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A B S T R A C T
Background: Osteosarcoma (OS) is the most common primary malignant bone tumour. Unfortunately, no new
treatments are approved and over the last 30 years the survival rate remains only 30% at 5 years for poor res-
ponders justifying an urgent need of new therapies. The Mutt homolog 1 (MTH1) enzyme prevents incorpo-
ration of oxidized nucleotides into DNA and recently developed MTH1 inhibitors may offer therapeutic
potential as MTH1 is overexpressed in various cancers.
Methods: The aim of this study was to evaluate the therapeutic benefits of targeting MTH1 with two chemical
inhibitors, TH588 and TH1579 on human osteosarcoma cells. Preclinical efficacy of TH1579 was assessed in
human osteosarcoma xenograft model on tumour growth and development of pulmonary metastases.
Findings: MTH1 is overexpressed in OS patients and tumour cell lines, compared to mesenchymal stem cells.
In vitro, chemical inhibition of MTH1 by TH588 and TH1579 decreases OS cells viability, impairs their cell
cycle and increases apoptosis in OS cells. TH1579 was confirmed to bind MTH1 by CETSA in OS model. More-
over, 90mg/kg of TH1579 reduces in vivo tumour growth by 80.5% compared to non-treated group at day 48.
This result was associated with the increase in 8-oxo-dG integration into tumour cells DNA and the increase
of apoptosis. Additionally, TH1579 also reduces the number of pulmonary metastases.
Interpretation: All these results strongly provide a pre-clinical proof-of-principle that TH1579 could be a ther-
apeutic option for patients with osteosarcoma.
Funding: This study was supported by La Ligue Contre le Cancer, la SFCE and Enfants Cancers Sante.
© 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license.
(http://creativecommons.org/licenses/by-nc-nd/4.0/)
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1. Introduction
Osteosarcoma (OS) is the most common primary malignant bone
tumour. It mainly affects children and young adults, with an inci-
dence peak at around 18 years old, and is mostly localized in long
bones [1]. OS involves deregulation of the equilibrium between bone
formation and bone resorption, which leads to ectopic bone
formation and osteolysis. Current strategies combine surgical tumour
excision and chemotherapy [2,3]. Unfortunately, 5 years survival rate
drops from 75% to 25% for bad responders [4,5], hence the urgent
necessity to develop new therapeutic strategies. In this context, DNA
damaging compounds are particularly interesting candidates. Indeed,
their antitumour effects have been known for over half a century
[6,7]. In normal cells, DNA damages lead to cell cycle arrest in order
to prevent transmission of genetic alterations during mitosis. Never-
theless, tumour cells have high tolerance to DNA damage, allowing
greater proliferation rates [8]. However this fast proliferation also
increases the chances of cell death through the transmission of fatal
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DNA damages to daughter cells. Therefore, several anticancer strate-
gies are based on the induction of DNA damages to tumour cells. For
example in OS cells, DNA damaging agents such as cisplatin, doxoru-
bicin and methotrexate have been used in clinic for decades to treat
the disease [1,8,9].
Recently, there has been a growing interest for antitumour capa-
bilities of the reactive oxygen species (ROS), notably through their
ability to induce DNA damage [10]. ROS can indeed interact with the
pool of free nucleotides, creating oxidized nucleotides. These oxonu-
cleotides can be integrated into the DNA double helix by a DNA poly-
merase, during replication, and disturb cellular processes [11]. Base
Excision Repair (BER) mechanism then lead to excision of oxonucleo-
tides from DNA by glycosylases such as the 8-oxoguanineglycosylase
1 (OGG1). However, this repair mechanism can be overwhelmed,
leading to cell death. The Mutt homolog 1 (MTH1) or Nudix-Type 1
(NUDT1) protein is part of the nudix family of hydrolases. MTH1 acts
as a nucleotide pool sanitation enzyme by hydrolysing oxonucleoti-
des triphosphates such as 8-oxo-dGTP, 2-OH-dATP or 8-oxo-dATP,
into their monophosphates counterparts. Its activity prevents the
integration of oxidized nucleotides into DNA, since monophosphate
nucleotides cannot be used by the DNA polymerase [12,13]. Thus,
MTH1 protects cells against ROS effects on DNA integrity. Therefore,
targeting MTH1 could imply impairing the genome integrity, i.e.
through the targeting of DNA building blocks, nucleotides. Free
nucleotides are also more likely to be oxidized by ROS than DNAmac-
romolecules [12]. Furthermore, ROS are by-products of cell metabo-
lism [14], and it has been shown that tumour cells produce high
quantity of ROS compared to normal cells, due to their fast metabo-
lism, their environment and mutations [1517]. Consequently,
tumour cells could strongly depend on MTH1 activity to protect their
genome integrity, and thus increase its expression compared to nor-
mal cells. MTH1 has indeed been found to be overexpressed in sev-
eral types of cancer such as breast and colorectal cancer [18,19],
while MTH1-deficient mice developed spontaneous tumours 18
months after birth [20]. Since 2014, several studies have tested the
effects of MTH1 inhibition in different cancer types including osteo-
sarcoma, melanoma, breast, cervical or colorectal cancer. MTH1 inhi-
bition reduced cell viability and colony formation, increased oxidized
nucleotides integration in DNA, and induced DNA damage [2124].
In vivo, MTH1 inhibition decreased tumour growth and increased sur-
vival in mouse xenograft models [2123], leading to an increased
interest in MTH1 as therapeutic target in cancer [21,22]. But more
recently, these results were challenged by questioning the role of
MTH1 in tumour biology, as well as the benefits of targeting this pro-
tein in cancer [2528].
In this study we investigated the therapeutic efficacy of TH588
(first generation of MTH1 inhibitor) and TH1579 (optimized ana-
logue of TH588), in OS. TH1579 (Karonudib) is currently in a phase I
clinical trial. Using a panel of human OS cell lines and a xenograft
model, we evaluated the effects of TH588 and TH1579 on several
tumour processes such as proliferation, tumour growth or meta-
static dissemination.
2. Materials and methods
2.1. Tumour cell lines
Human osteosarcoma cancer cell lines HOS-MNNG, KHOS, MG63,
U2OS, SJSA-1, G292, Cal72 and 143B were purchased from the ATCC
and maintained in DMEM (Invitrogen-Life Technologies, Inc.) supple-
mented with 10% FBS and 2mmol/L l-glutamine. All cell lines were
cultured in a humidified 5% CO2/air atmosphere at 37 °C.
2.2. Tissue specimens and mesenchymal stem cells
Patient tumour biopsy specimens were collected at Nantes Uni-
versity Hospital (Nantes, France). Samples were obtained following
patient in formed consent, and after ethical approval by the Nantes
University Hospital Ethics Committee.
Human mesenchymal stem cells (hMSCs) from healthy donors
and osteoblasts derived from hMSCs on osteogenic differentiation
are used as controls. Briefly, hMSCs are cultured in DMEM supple-
mented with vitamin D3 and dexamethasone. Then ascorbic acid
and b-glycerophosphate was added to osteogenic medium. Before
their use, the cells induced to osteogenic differentiation were tested
for mineralization using alizarin red staining as described previ-
ously [29].
2.3. Therapeutic agent
MTH1 inhibitors, TH588 and TH1579 [21,22] was provided by the
Karolinska Institutet and used for in vitro and in vivo studies. For the
in vitro studies, the drugs were dissolved in dimethyl sulfoxide
(DMSO) at 10mmol/L stock solution and stored at 20 °C. For in vivo
studies, TH1579 was dissolved in an acetate plus cyclodextrin buffer
at the indicated concentrations.
2.4. Cell proliferation assay, clonogenic assay and apoptosis assay
OS cells were seeded in 96 wells plates. 24 h after seeding, OS cells
were treated with the drugs at the indicated doses (from 78 nml/L to
20mmol/L). After 72 h of treatment, the cells were fixed with 1% glu-
taraldehyde under agitation for 5 min, washed with water then
stained with 0.1% crystal violet for 5 min. After drying, the dye was
diluted in Sorensen’s buffer (5 min in trisodium citrate, HCl 0,1N and
ethanol) and the absorbance was measured at 570 nm using a spec-
trophotometer (Perkin Elmer Wallac 1420 Victor2). The proliferation
rate is represented as a percentage of untreated cells.
Regarding the clonogenic assay, cells were treated for 48 h with 2
or 8mmol/L of TH588 or TH1579. The cells were then trypsinated
and plated at 1000 cells/well in 6 wells plate. 10 days later, the cells
were fixed and stained with crystal violet as described above. The col-
onies were then counted.
Research in context
Evidence before this study
Osteosarcoma is the most prevalent primary malignant bone
tumour with poor prognosis mainly affecting children and young
adults. Since current therapies did not change in the last 30 years,
there is a real need of new therapeutic strategies. Targeting MTH1
using TH1579 has shown to inhibit tumour growth in preclinical
studies in various cancers.
Added value of this study
Using in vitro experiments and mouse models of osteosarcoma,
we report that TH1579, MTH1 inhibitor, inhibits cell growth
and induces apoptosis in osteosarcoma cells and, delays tumour
growth and blocks the development of pulmonary metastases
in preclinical model of osteosarcoma.
Implications of all the available evidence
In this study, we provide the new insight in the therapeutic effi-
cacy of TH1579 on tumour growth and metastases develop-
ment in preclinical model of osteosarcoma suggesting that
TH1579 could be a therapeutic option in treatment of patient
with osteosarcoma.
2 B. Moukengue et al. / EBioMedicine 53 (2020) 102704
2.5. Transfection and transduction
OS cells were transfected with 30 nmol/L of siRNA (sc-62647,
sc-37007; Santa Cruz Biotechnology) using Lipofectamine RNAi-
max (thermofisher scientific) following the provider’s recommen-
dation. For the transduction, the shRNA (MOI20) targeting MTH1.
pLKO.1shMTH1-1 and shMTH1-2 was a gift of Bob Weinberg
(Addgene plasmids # 21297 and # 21298) [30]. The proliferation
assay was performed as described above (without treatment), on
cells trypsinated and re-seeded after 48 h of transfection or 72 h of
transduction.
2.6. Apoptosis assay
Caspase activity was measured in protein extract using the Apo-
ONE caspase 3/7 kit from Promega. The cells were treated for 48 h
and the assay was performed according to the supplier’s recommen-
dation. The fluorescence was measured at 521 nm on the Tristar LB
941 (Berthold Technologies). The enzymatic activity was normalized
by the protein quantity.
2.7. Cell-cycle analysis
Osteosarcoma cell were treated at indicated concentrations of
TH588 or TH1579 for 48 h, trypsinized, washed twice, in cold PBS
(5 min), and fixed with 70% ethanol at 4 °C for 30 min. After washing,
cells were incubated for 10 min in 4 °C phospho-citrate buffer,
washed and incubated in PBS containing 100mg/mL ribonuclease A,
for 30 min at 37 °C. Cells were then incubated in 50mg/mL propidium
iodide for 20 min at 4 °C. Cell-cycle distribution was analysed by flow
cytometry (Beckman Coulter Epics Elite, Beckman Coulter), based on
2 N and 4N DNA content.
2.8. Comet assay
OS cells were treated with TH588 or TH1579 for 24 h, then trypsi-
nated, included in low melting agarose (37 °C) and put on Superfrost
plus slides (ThermoFisher scientific). The cells were then lysated
overnight at 4 °C, in a DMSO, NaOH, triton and TrisHCl containing
buffer. The cells were then washed in a digestion buffer (Hepes, KCl,
500mmol/L EDTA and BSA in water; 3£ 20 min) and treated with
2mG OGG1 (diluted in the digestion buffer) when indicated, for
45 min at 37 °C. After 30 min in a denaturation buffer (EDTA, 10 N
NaOH in water), an electrophoresis was performed at 300mA, for
30 min in the denaturation buffer. The slides are then dipped in a pH
7.5 neutralization buffer for 45 min (Tris and HCL in water). DNA
breaks are detected using the Thermofisher Sybr Gold dye and quan-
tified using FIJI and the Open Comet plugin.
2.9. 8-oxo-dG assay
It is well known that Avidin binds with high specificity to 8-oxo-
dG and used to evaluate the incorporation of 8-oxo-dG into DNA
[31]. Tumour cells were treated with TH1579 at indicated concentra-
tions for 24 h in slide 8 wells (Ibidi). Then, cells were fixed in metha-
nol at 20 °C for 20min following by incubation in TBS with 0.1%
Triton X-100 for 15min. Cells were incubated in blocking solution
(15% FBS, 0.1% Triton X-100 in TBS) for 2 h at room temperature, and
thereafter incubated with 10mg/mL Alexa488-conjugated Avidin
(Invitrogen) in blocking solution for 1 h at 37 °C. Then, the cells were
washed in TBS 0.1% Triton X-100 for 2£ 5min at room temperature,
following by a quick rinse in distilled water. DNA was counterstained
with DAPI for 15min in dark at room temperature. The cells were
rinsed in TBS and Ibidi mounting Medium were added in the wells of
the slides. Images were acquired with the Olympus IX73 inverted
microscope.
2.10. Quantitative reverse transcription PCR
Total RNA was extracted using the Macherey-Nagel Nucleospin
RNA. Following a reverse transcription on 1mg of total RNA, the cDNA
were diluted to 10 ng/mL. A Real-time monitoring of PCR amplification
of cDNA was performed using DNA primers (Supplementary Table I)
on CFX96 Detector System (Bio-Rad) with SYBR PCR Master Mix (Bio-
Rad). Target gene expression was normalized to GAPDH level in
respective samples as an internal standard, and the comparative cycle
threshold (Ct) method was used to calculate relative quantification of
target mRNAs. Each assay was performed in triplicate.
2.11. Western blot
Samples containing equal amounts of protein from lysates of cul-
tured osteosarcoma cells underwent electrophoresis on SDS-poly-
acrylamide gel and were transferred to PVDF membranes blocked in
odyssey blocking buffer (LI-COR). Blots were probed overnight at 4 °C
with primary antibodies (Supplementary Table II). After incubation,
the membranes were washed in PBS containing 0.05% Tween. Mem-
branes were then probed with a fluorescent antibody (Li-COR IRDye)
diluted in the odyssey blocking buffer. Antibody binding was visual-
ized using the LI-COR odyssey Fc.
2.12. Immunofluorescence
Cells were cultured in an imaging chamber (Ibidi) and treated as
indicated in the figure. As control, cells were irradiated at 15 Gy,
delivered at a rate of 1,67 Gy/min (Faxitron CP160 irradiator, Faxitron
X-ray Corporation, IL, USA). Then, cells were fixed with 4% parafor-
maldehyde for 20min at room temperature, then washed (washing
buffer: PBS-Tween20 0.05%) and permeabilized 10min at room tem-
perature with PBS-0.1% triton X100. Cells were then blocked 10min
with goat serum (1/200) in washing buffer, then incubated overnight,
at 4 °C, with primary antibody (Cell signalling Technology gH2AX
antibody). Afterward, cells were washed and incubated with alexa
Fluor 488 antibody (60min at room temperature), then with DAPI.
2.13. Transwell motility and invasion
Cell migration and invasion assays were performed in Transwell
chamber (8-mm pore size; Falcon). For cell invasion experiments,
inserts were coated with 100 mL basement membrane Matrigel
(3mg/ml; Becton Dickinson) for 90 min at 37 °C. HOS-MNNG cells
(1£ 105 cells/mL) were resuspended in DMEM containing 0.1% FBS,
and 300 mL of this cell suspension was loaded into each insert
(top chamber). DMEM 10% FBS was placed in the bottom chamber
(750 mL/well). The plates were incubated for 6 h at 37 °C for migra-
tion and 24 h for invasion. Then, the inserts were carefully collected,
the non-migrating cells were removed, and the migrating cells on
the under-surface of the inserts were fixed with 1% glutaraldehyde
under agitation for 5 min, washed with water, and then stained
with 0.1% crystal violet for 5 min. The cells were then counted by
bright-field microscopy.
2.14. Animal treatment
Female athymic nude mice were injected intramuscularly close to
the tibia with 1.5£ 106 HOS-MNNG cells. Once their tumours were
palpable, mice were randomly assigned to vehicle, TH1579 45mg/kg
or TH1579 90mg/kg groups and treated orally b.i.d daily three times
per week until day 48. Each experimental group consisted of 8 mice.
Tumour volume was measured three times per week. Tumour volume
was calculated by the formula: length£width£ depth£ 0.5432. Data
points were expressed as average tumour volume § SEM. Tumours
and tibia were harvested for further analyses [micro computed
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tomography (microCT), histology]. Animal care and experimental pro-
tocols were approved by the French Ministry of Research and were
done in accordance with the institutional guidelines of the French Ethi-
cal Committee protocol agreement number 1280.01 and under the
supervision of authorized investigators.
2.15. MicroCT analysis
Tibias were scanned using high-resolution microcomputed
tomography (Skyscan 1076) at 50 kV and 200mA using a 0.5mm alu-
minium filter and a detection pixel size of 9mm. Images were cap-
tured every 0.8° through 180°rotation, and analysed using Skyscan
software. After scanning, 3D microstructural image data was recon-
structed using the Skyscan NRecon software. Bone parameters were
calculated using the Skyscan CT Analyzer (CTAn) software. Using this
software, the volume of interest was defined as cortical remodelling
bone. Binarized images were performed: an upper threshold of 255
and a lower threshold of 55 was used to delineate each pixel as
“bone” or “non-bone”Morphological traits of the mid-diaphyseal cor-
tical shell were performed at a site starting 200 slices from the pero-
nea insertion and then extending from this position for 700 slices
(each slice = 9mm). Then, total cross sectional area (Tt.Ar), cross sec-
tional cortical area (Ct.Ar), cortical bone fraction (Ct.Ar/Tt.Ar), cortical
thickness (Ct.Th), and cross sectional moment of inertia (polar)
(CSMI) was measured in 2D.
2.16. Immunohistochemistry
IHC was performed on formalin-fixed, paraffin-embedded 3mm
sections of tumour samples. Immunostaining was conducted using
the primary antibodies cleaved caspase-3 (1/400; Cell signalling
Technology), CD146 (1/200; Abcam), gH2AX (1/750; Millipore), 8-
oxo-dG (1/750; Millipore) and Sp7/Osterix (1/1000; Abcam) on
tumour section.
Tibias were decalcified with 4.13% EDTA and 0.2% paraformalde-
hyde in PBS using the KOS microwave histostation (Milestone) before
embedding in paraffin. Sections (Leica Microsystems) were analysed
by Osterix and TRAP staining. Quantification of relative OC surface
(TRAP+ cells) and OB number (Osterix+ cells) was evaluated by
ImageJ (NIH, Bethesda, MD) software. All analyses were assessed by
slide scanning using nanozoomer 2.0 RS (Hamamatsu).
2.17. Cellular thermal shift assay (CETSA)
CETSA is a target engagement assay detecting potential interaction
between a specific target and studied compounds and has been
described previously [32]. Briefly, frozen tumours from the TH1579
and vehicle treated animals were grinded in liquid nitrogen then
resuspended in 600ml TBS-T complete protease inhibitor cocktail
(Roche). Aliquots were incubated for 3min at a temperature gradient
of 5066 °C. Samples were frozen (80 °C) and thawed (25 °C) three
times to lyse the cells, followed by centrifugation at 17,000 g for
30min. The supernatant (35ml/sample) was transferred to a 96-well
PCR plate (Agilent) and 12ml of 4x Laemmli sample buffer were added
to each sample. Proteins were denatured by heating the PCR plate at
95 °C for 10min. Samples were run on SDS-PAGE and transferred to
nitrocellulose membranes and incubated with rabbit anti MTH1 anti-
body (Novus Biological). Membranes were developed using Super Sig-
nal West Femto Substrate (Thermo Scientific), and measurements
were performed using Odyssey Imaging System (LI-COR) and the
bands signals were quantified using Odyssey image software.
2.18. Osteoclast differentiation assays
Osteoclasts were generated from human CD14+ monocytes of dif-
ferent donors. Purified CD14+ cells were cultured in a-MEM
(Invitrogen Life Technologies) with 10% FBS and 25 ng/mL human
macrophage colony stimulating factor (hM-CSF; R&D Systems). After
4 days, 100 ng/mL hRANKL +/- TH1579 were added. Multinucleated
cells with more than three nuclei were counted after Tartrate-Resis-
tant Acid Phosphatase (TRAP) staining (Sigma, France).
2.19. Short term in vivo study using HOS-MNNG-GFP cells
Procedures involving animal handling and care were approved by
the Animal Care and Ethics Committee of the Home office in UK [PPL:
70/8967, Establishment license n°: 50/2509] and performed by
trained, licensed personnel. To assess effects of short-term treatment
with TH1579 on disseminated tumour cells (DTCs) to the lung and
circulating tumour cells (CTCs) a paratibial osteosarcoma model was
used. Briefly, 2.5£ 105 HOS-MNNG-GFP cells were injected parti-
bially into anaesthetized female Balb/c nude mice (67 weeks old).
Five days later animals received treatment of either vehicle or
TH1579 at 90mg/kg b.i.d three times per week for one week by oral
gavage. Animals were culled 24 h (TH1579 group) or 48 h (vehicle
group) after the last treatment. The tumour bearing leg was mea-
sured using callipers and the volume was calculated before assessing
DTCs, CTCs.
2.20. Quantification of DTCs and CTCs using Parsortix
Animals were culled just before sample preparation for DTC anal-
ysis. Whole blood was collected via cardiac puncture into EDTA vacu-
tainers (BD). Blood from all animals in one group was pooled. Lungs
were excised, washed in PBS and minced using a scalpel blade before
adding tumour dissociation solution (Tumour Dissociation Kit, Mylte-
nyi) for 30 min at 37 °C. The single cell suspension was then filtered
and centrifuged before resuspending in PBS and loading onto the Par-
sortix system (Angle) using the PX2_S50F separation program and a
6.5 mm separation cassette. Briefly, the Parsortix system is a micro-
fluidic technology, which allows enrichment, isolation and quantifi-
cation of small numbers of tumour cells based on cell size on
deformability. The separation cassette containing the enriched sam-
ple was then vizualized using a fluorescent microscope and GFP-posi-
tive tumour cells trapped in the cassette were counted. As indicative
experiment, the same procedure was performed for CTCs in whole
blood (blood in each group was pooled before analysis; control N = 2;
TH1579, N = 3) using PX2_S99F separation program.
2.21. Statistical analysis
All statistical tests were performed using the Graphpad Prism
software. Statistical significativity was assessed by KruskalWallis
test or Anova. * p < 0.05; ** p < 0.01, ***p < 0.001, ****p < 0.0001.
3. Results
3.1. MTH1 mRNA level is overexpressed in osteosarcoma
We first evaluated MTH1 mRNA expression level of in 13 human
OS patient samples (Fig. 1a and 1b) and 7 OS cell lines (Fig. 1c and d).
Compared to normal mesenchymal stem cells (Msc) or osteoblasts
derived from hMSC (OB) from healthy donors, MTH1 was overex-
pressed in all patient samples at mRNA level, and in all OS cell lines
tested at mRNA and protein levels.
3.2. TH588 and TH1579 reduce osteosarcoma cell proliferation
The effects of TH588 and TH1579 were evaluated on cell growth,
in 8 OS cell lines (Fig. 2a). In all tested cell lines, TH588 and TH1579
inhibited cell growth in a dose dependent manner, with IC50 values
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ranging from 4.48mmol/L to 17.37mmol/L for TH588, and from
0.31mmol/L to 16.26mmol/L for TH1579 (Fig. 2b).
Colony formation assays was performed after 48 h of TH588 or
TH1579 treatment and showed that both drugs significantly reduced
tumour cells clonogenicity in HOS-MNNG and U2OS cell lines
(Fig. 2c). Indeed, number of colonies was reduced by 53.4% in HOS-
MNNG cells treated with 2mmol/L of TH588 and by 91.5% when
treated with 8mmol/L of TH588 (p < 0.001). Likewise, number of
U2OS colonies was respectively reduced by 13% and 91% (p < 0.001)
when treated with 2mmol/L and 8mmol/L of TH588, respectively.
For TH1579, number of colonies in both cell lines was reduced by
over 90% for each concentration (p < 0.001). Similar results were
observed 143B, Cal72, G292, KHOS, MG63 and SJSA-1 cell lines (Sup-
plementary Fig. S1).
In order to evaluate whether these results were linked to specific
MTH1 inhibition, we transfected or transduced HOS-MNNG cells
with a mix of two specific siRNA or two different shRNA targeting
MTH1. The decrease of MTH1 expression was validated by qPCR
(Supplementary Fig.S2) and Western blot (Fig. 2d). Specific MTH1
inhibition reduced cell growth by 16% compared to control siRNA
(p < 0.01), and by 66% (p < 0.001) and 48% (p < 0.01) respectively,
for MTH1 shRNA-1 and 2 treatment (Fig 2d).
Fig. 1. MTH1 is overexpressed in osteosarcoma. (a) Expression of MTH1 was evaluated by RT-qPCR in 13 human osteosarcoma biopsies and compared to human mesenchymal stem
cells (hMSC) or osteoblast derived from differentiation of MSCs (OB) from healthy donors. (b) Clinical features of osteosarcoma patients. (c) Expression of MTH1 in human osteosar-
coma cell lines was also evaluated by RT-qPCR and compared to hMSC and OB from healthy donors. Errors bars show SD. (d) Expression of MTH1 in human osteosarcoma cell lines
was also evaluated by Western blot and compared to hMSC from healthy donors and analysed using Empiria Studio software (Licor).
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Fig. 2. MTH1 inhibition decreases cell proliferation in human osteosarcoma cell lines. (a) Human osteosarcoma cell lines (143B, Cal72, G292, HOS-MNNG, KHOS, MG63, SJSA-1 and
U2OS) were cultured for 72 h with TH588 or TH1579 at the indicated concentrations, and cell growth was determined by a crystal violet assay. The expression of an untreated popu-
lation was equalled to 100%. (b) IC50 for TH588 and TH1579 in tumour cell lines was calculated. (c) HOS-MNNG and U2OS osteosarcoma cells were treated with 2 or 8mM of the
indicated drugs for 48 h then plated at clonal density for colony counts. (d) HOS-MNNG cells were transfected with siRNA (30 nM) or transduced with different shRNA targeting
MTH1 (MOI 20). Cell viability was compared to controls after crystal violet staining (NT: non transfected, siCt: control siRNA, shLacZ: control shRNA). Error bars show SD Statistical
significativity was assessed by KruskalWallis test. * p < 0.05; ** p < 0.01, ***p < 0.001.
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3.3. TH1579 induces apoptosis by increasing DNA strand breaks
Since the TH1579 compound being the most potent drug in this
study, we focus the rest of the study on TH1579. Using this drug, we
investigated the effect of TH1579 on cell cycle using propidium
iodide staining after 48 h of treatment (Fig. 3a). At 500 nM, TH1579
induces G2/M arrest in HOS-MNNG cells as shown by 49% of cells in
G2/M phase compared to 11% of cells in control condition. Moreover,
in both HOS-MNNG and U2OS cells, TH1579 increased cells death
(subG0/G1 fraction) in a dose-dependent manner compared to con-
trol. For HOS-MNNG cells, 4% of cells were in the subG0/G1 fraction
in the control condition, while 31% and 39% of cells for the 2mM and
8mM TH1579 respectively. For U2OS cell line, 8%, 69% and 67% of
cells were in the subG0/G1 fraction for control, 2mM and 8mM of
TH1579 conditions, respectively. Indeed, TH1579 induced apoptosis
as shown by a significant increase of caspase 3/7 activity compared to
non-treated control (e.g. by 2-fold after 8mM TH1579 treatment vs
control in U2OS cells, p < 0.01; by 6-fold after 8mM TH1579 treat-
ment vs control in HOS-MNNG cells, p < 0.01; Fig. 3b). Same results
were obtained for TH588 (Supplementary Fig. S3a and S3b). Induc-
tion of apoptosis was also confirmed by an increase in PARP cleavage
in treated conditions compared to the control (Fig. 3c).
Since MTH1 prevents oxonucleotides integration into DNA, we
measured the DNA damage induced by TH1579 +/- OGG1 using
comet assay (Fig. 3d). OGG1 is a glycosylase that excises the 8-oxo-
dG nucleotide from the double helix, inducing DNA breaks and initi-
ating the DNA repair process. In U2OS cells, combination TH1579
+OGG1 treatment increased the tail moment compared to controls
(Fig. 3d). The tail moment was increased by 3,93-fold in TH1579
+OGG1 compared with untreated control condition (p < 0.001), by
3.88-fold compared with OGG1 condition (p < 0.001), and by 1.3-fold
compared with TH1579 alone (p < 0.001), indicating that TH1579
induces DNA strand breaks probably by enhancing 8-oxo-dG integra-
tion into DNA. We confirmed the incorporation of 8-oxo-dG into DNA
after treatment with TH1579 compared with control in OS cells as
shown by an accumulation of 8-oxo-dG in the nucleus (counter-
stained with DAPI) observed by immunofluorescence (Fig. 3e).
Consequently, we next evaluated the DNA damage induced by
TH1579. We analyzed the expression of phosphorylation on serine
319 of H2AX histone (gH2AX) known to be a marker of DNA double
strand breaks [33,34]. TH1579 increased gH2AX expression in U2OS
cells (Fig. 3f). However, we failed to show a significant impact of the
treatment on gH2AX expression, using immunofluorescence, as
gH2AX expression was very heterogeneous: some cells displayed a
high number of foci expression while other showed a low number of
foci (Supplementary Fig.S4).
3.4. TH1579 delays tumour growth and increases DNA damages in HOS-
MNNG xenograft model
Therapeutic potential of TH1579 was next evaluated in vivo in an
OS xenograft model. Mice bearing HOS-MNNG tumours, which is an
OS xenograft model reproducing the human pathology associated
with development of pulmonary metastases, were randomly sepa-
rated in three groups and orally treated 3 times per week with vehi-
cle, 45mg/kg of TH1579 or 90mg/kg of TH1579 for 48 days. No
significant change of body weight was observed at these concentra-
tions. TH1579 treatment significantly decreased the tumour volume
in both treated groups in a dose dependent-manner, compared to
control group (Fig. 4a and b). At day 29, the mean tumour volume
was diminished by 40.6% in the 45mg/kg group (398mm3§
57,2mm3, p = 0,23), and 73.2% in the 90mg/kg group (179.46mm3 §
39,4mm3, p < 0.001), compared to control (670.3mm3 § 99mm3).
At day 48, the mean tumour volumes were reduced by 41.3%
(1105.3mm3 § 153,7mm3, p = 0,22) and 80.6% (365.96mm3 §
81,6mm3, p < 0,001) in the 45mg/kg and the 90mg/kg groups
respectively, compared to control (1883.09mm3 +/- 272,3mm3;
Fig. 4A). At the individual level, the incidence of mice with a tumour
volume of 1000mm3 or greater was significantly reduced by day 48
in both TH1579 90mg/kg-treated mice (0/8) and TH1579 45mg/kg-
treated mice (4/8) compared with control mice (8/8; Fig. 4b).
Moreover, the target engagement evaluated by Cellular Thermal
Shift Assay (CETSA) is increased in a dose-dependent manner in
tumour tissue following TH1579 treatment (Supplementary Fig.S5).
Immunohistochemistry staining carried out on tumour tissues
indicated that TH1579 increased tumour cell death as shown by a sig-
nificant increase of cleaved-caspase 3 expression by 6% and 8.5% in
the 45mg/kg (p < 0.05) and the 90mg/kg (p < 0.001) groups respec-
tively, compared to the control group (Fig. 4c). These data indicate
that TH1579 induces apoptosis in vivo.
Added to this, effects of TH1579 treatment on 8-oxo-dG integra-
tion into DNA and DNA damage were evaluated in tumours by immu-
nohistochemistry, using 8-oxo-dG and gH2AX antibodies. TH1579
significantly increased 8-oxo-dG integration and DNA damage in
treated groups compared to control. Indeed, in TH1579 45mg/kg
group for example, 8-oxo-dG expression was increased by 2-fold
(p < 0.05) and gH2AX expression was increased 1.4-fold (p < 0.01)
compared to control. In TH1579 90mg/kg group 8-oxo-dG and
gH2AX were respectively increased by 2.6-fold (p < 0.01) and 1.38-
fold (p < 0.05) compared to the control group (Fig. 4c).
3.5. TH1579 reduces pulmonary metastases by inhibiting migration and
angiogenesis
Thereafter, effects of TH1579 on metastases development were
evaluated in HOS-MNNG xenograft model. Lung metastases were
counted in each experimental group after H&E coloration. The aver-
age number of metastases was reduced by 45% (average of 2.06
metastases) in 45mg/kg TH1579 group, and significantly reduced by
86.7% (average of 0.5 metastasis) in 90mg/kg group (p < 0.001), com-
pared to control (average of 3.75 metastases; Fig. 5a).
Moreover, TH1579 also reduced the number of Circulating
Tumour Cells (CTC) counted in blood and Disseminated Tumour Cells
(DTC) counted in dissociated lungs of mice bearing HOS-MNNG-GFP
tumours after one week treatment of 90mg/kg TH1579 compared to
control group, suggesting an effect of TH1579 on metastatic dissemi-
nation. Indeed, while the mean tumour volume of the two groups
(90mg/kg TH1579 vs vehicle) was equivalent (89.6 mm3 and
96.1 mm3 for the control and treated conditions respectively; Supple-
mentary Fig. S6), the number was 61 CTC/mL of blood in control
group, and 13 CTC/mL in 90mg/kg TH1579 group. DTC number in
lungs was also reduced by 2.68-fold after 90mg/kg TH1579 (25 GFP-
positive tumour cells) treatment compared to control group (68 GFP-
positive tumour cells; Fig. 5b). One of the mice from the control group
was excluded from the analysis since it did not have a visible GFP+
tumour.
In order to verify that TH1579 could affect processes involved in
metastases, migration and invasion assays were performed on HOS-
MNNG cells treated with TH1579. In the migration assay using trans-
wells, number of migrating cells was significantly reduced by 70%
(p < 0.01) and 73% (p < 0.001) after treatment with 2mM TH1579
(113 cells) and with 8mM TH1579 (102 cells) respectively, compared
to control (388 cells). In the invasion assay, number of cells per field
was significantly reduced by 32.8% (p < 0.01) after treatment with
2mM TH1579, and 69.44% (p < 0.001) after treatment with 8mM
TH1579. TH1579 significantly reduced both migration and invasion
capabilities of HOS-MNNG cells (Fig. 5c).
According to migration and invasion assays, TH1579 significantly
reduced angiogenesis, as shown by a reduced CD146 expression in
tumours treated with 90mg/kg TH1579 (1.27 times lower) compared
to control group (p < 0.01; Fig. 5d). No significant change was
observed between 45mg/kg TH1579 and control groups (Fig. 5d).
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Fig. 3. MTH1 inhibition disrupts cell cycle and induces apoptosis in osteosarcoma cells. (a) HOS-MNNG and U2OS cells were treated with 100 nM or 500 nM (low dose) and 2 or
8mM (high dose) TH1579 for 48 h, and the proportion of cells in subG1, G0G1, S, G2M was determined by propidium iodide staining and flow cytometry. (b-c) Tumour cells
were treated with TH1579 at the indicated concentrations and apoptosis was evaluated by a caspase 3/7 assay and cleaved poly (ADP-ribose) polymerase (PARP) expression using
western blotting. (d) U2OS cells were treated with 8mM TH1579 for 24 h, and modified comet assay was performed to evaluate DNA damage (+/- OGG1). The tail moment was cal-
culated using FiJi and the Open comet plugin. (e) U2OS cells were treated with TH1579 at indicated concentrations for 24 h and 8-oxo-dG incorporation into DNA was evaluated by
fluorescence using Alexa488-conjugated Avidin (scale bar 100mm). (f) gH2AX expression was evaluated by western blot in U2OS cells, after 48 h of treatment with TH1579 at the
indicated doses. Error bars show SD. Statistical significativity was assessed by KruskalWallis or Anova. ** p < 0.01, ***p < 0.001.
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Fig. 4. TH1579 significantly delays tumour growth in a HOS-MNNG xenograft model. Mice were orally treated with vehicle, 45mg/kg or 90mg/kg TH1579 twice a day, 3 days a
week until day 48, when the tumour volume reached 100mm3. The mean tumour volume (a) or the individual tumour volume (b) of the treated mice were compared to the control
group +/- SEM (n = 8). (c) Tumours were collected after 48 days, 8-oxo-G, cleaved-caspase-3 and gH2AX were evaluated by immunohistochemical analysis (scale bar 100mm). Sta-
tistical significativity was assessed by Anova (tumour growth) or KruskalWallis. Error bars show SEM. * p < 0.05; ** p < 0.01, ***p < 0.001.
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Fig. 5. TH1579 decreases lung metastases in a HOS-MNNG xenograft model. (a) Lung metastases were counted after hematoxylin-eosin coloration (HE; scale bar 1mm, except for
the zoom: scale bar 100mm as mentioned in the figure). (b) Circulating (CTC) and disseminated (DTC) tumour cells were counted in two groups of OS mice: non treated or treated
with 90mg/kg of TH1579 for one week. (c) TH1579 effect on invasion and migration was evaluated in vitro, on HOS-MNNG cells, by a migration assay and an invasion assay respec-
tively. Cells were plated in non-coated boyden chambers (migration) or coated with 2mg of matrigel (invasion) with the indicated TH1579 concentrations, for 6 h (migration) or
24 h (invasion). (d) Neo-angiogenesis was evaluated by CD146 staining, by immunohistochemical (scale bar 100mm) and quantified using ImageJ. Error bars show s.d. Statistical sig-
nificativity was assessed by KruskalWallis or Anova. ** p < 0.01, ***p < 0.001.
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Fig. 6. TH1579 effect on bone lesions. (a) Representative microCt image of tibias bearing the tumour in the 3 groups. (b) Quantification of the Bone Volume (BV) and BV/TV (Total
Volume) parameters. (c) Quantification of the IHC staining of TRAP and Osterix using ImageJ (scale bar 100mm) and represented as number of osteoblasts on bone surface (OB num-
ber/BS) and number of osteoclasts on bone surface (OCs/BS). (d) CD14+ cells viability was assessed using crystal violet after TH1579 treatment as indicated concentration. Osteoclast
differentiation was assessed after treatment of CD14+ cells with 25 ng/mL human macrophage colony stimulating factor (hM-CSF) and 100 ng/mL of hRANKL +/- TH1579 at the indi-
cated concentrations. Osteoclasts number was evaluated after TRAP staining at day 11. Negative control (CT -) represents CD14+ cells treated with 25 ng/mL hM-CSF without human
RANKL. Positive control (CT+) represents cells treated with 100 ng/mL of hRANKL. DMSO represents CT+ treated with DMSO. Error bars show s.d. Statistical significativity was
assessed by KruskalWallis. * p < 0.05; ** p < 0.01.
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3.6. Effect of TH1579 on tumour-associated bone lesions
In order to evaluate the effect of TH1579 on tumour associated-
osteolysis, cortical and trabecular bone parameters of tibia bearing
tumours were examined (Fig. 6a and b). BV was identical between
TH1579 treated (45mg/kg and 90mg/kg) and control groups. BV/TV
was slightly but not significantly increased by 17% in 90mg/kg
TH1579 group compared to control group (p value = 0.0508).
Immunohistochemical staining of osterix showed an increase of
osteoblasts (OB) number over bone surface (BS) in both treated
groups (2.08 and 3.95 OB/BS for the 45mg/kg and 90mg/kg condi-
tions respectively), compared to control group (1.25 OB/BS). Likewise,
TRAP staining also showed a significant increase of osteoclast number
over bone surface in treated groups compared to control group
(Fig. 6c). Ocs/BS was 2.9 times more important after treatment with
45mg/kg TH1579 and 3.9 more important after treatment with
90mg/kg TH1579 compared to control. Effects of TH1579 on bone
cells were also evaluated in vitro on CD14+ osteoclast precursors as
well as hMSC osteoblast precursors. TH1579 reduced osteoclasts dif-
ferentiation, without any significant effect on their precursor’s viabil-
ity (Fig. 6d). However, TH1579 reduced both hMSC viability and
mineralization (Supplementary Fig.S7).
4. Discussion
Osteosarcoma is a paediatric cancer with poor prognosis and high
recurrence. Since 30 years, treatments are limited to chemotherapy
associated with resistance development. Finding new therapeutic strat-
egies for OS is urgently needed. In this context, the enzyme MTH1 is an
attractive target since MTH1 is “druggable” by chemical compounds
(TH588, TH1579, S-Crizotinib). MTH1 is described to support malignant
transformation, proliferation and oncogenic ability through the degra-
dation of oxidized guanine nucleotides from oxidative stress
[21,23,35,36]. OS exhibits a high level of ROS suggesting a potential
constitutive activation of MTH1 in tumour cells. Indeed, we observed
an overexpression of MTH1 in OS biopsies as well as in a large panel of
OS cell lines with various genetic alterations compared to hMSC.
Despite controversial opinions in literature about the dependence
of MTH1 by cancer cells to survive and the efficiency of therapeutic
drugs under development [2528], we aimed to evaluate the thera-
peutic efficacy of the MTH1 inhibitors, TH588 and TH1579 in OS
model. In the present study, we clearly observed anti-tumour activity
of both TH588 and TH1579 in OS cell lines with higher activity of
TH1579 as shown by significant decrease of cell viability associated
with increase of apoptosis as already described in the literature
[21,22,37,38]. Indeed, TH1579 is more potent to inhibit MTH1 activity
than TH588 [22], and is currently in phase 1 clinical trial in various
advanced solid malignancies otherwise known as Karonudib
(NCT03036228). TH1579 exhibits high anti-tumour activity through
a dual mechanism of action, by inducing toxic 8-oxodG lesions into
the DNA, that can be reversed by expression of the bacterial MutT
enzyme [22], and also through arrest of cells in mitosis by inhibition
of microtubule polymerisation. The detailed mechanism of action is
complex as the MTH1 protein promotes tubulin polymerisation and
also directly binds tubulin [39]. Furthermore, TH1579, but not other
potent MTH1 inhibitors, breaks the tubulin-MTH1 interaction and
arrest cells in mitosis. To complicate matters even further the
TH1579 compound directly interfere with tubulin [39] which alto-
gether make up the mechanism of action of Karonudib. Here, we
want to evaluate the effect of TH1579 in OS and detailed understand-
ing of the mechanism of action falls outside the scope of this report.
However, when MTH1 was specifically knock-down using siRNA or
shRNA approaches, a reduction of cell viability of tumour cells was
shown, but less dramatically than the effects observed with TH588 and
TH1579, suggesting that MTH1 is probably not the only target of these
drugs in OS and deserved to be deeply studied. Several studies reported
that specific MTH1 inhibition does not affect tumour cell viability and/
or apoptosis such as reported in non-small cell lung cancer
[25,26,28,40]. While the cytotoxic effects of MTH1 inhibition in cancer
are controversial in literature, TH588 has been shown to be cytotoxic in
several studies [41,42]. We also found that TH588 and TH1579 induce
apoptosis by increasing DNA damage as shown by comet assay and
induction of H2AX phosphorylation in OS cells. These data are consis-
tent with early cellular response to DNA strand breaks as already
reported in the literature [33,43]. As reported in two studies TH588
induces a mitotic arrest with cells accumulation in G2/M phases in Hela
cells or in colorectal cancer [25,41], we also observed mitotic arrest
(G2/M blockage) in HOS-MNNG cell line after 48 h of treatment with
TH1579 (500 nM). But we cannot exclude that the observed apoptosis
associated with DNA damage could also beMTH1-dependent.
Our study further demonstrates that TH1579 strongly delayed
tumour growth in vivo associated with an increase of apoptosis and
DNA damage as shown by higher expression level of toxic 8-oxo-G
and gH2AX after TH1579 treatment. By using CETSA, we could show
that TH1579 binds to MTH1 inside the tumours of the treated mice in
a dose dependent manner. The drug seems to be well tolerated with
no toxicity observed. Additionally, TH1579 significantly reduced lung
metastases in vivo in OS xenograft model associated with reduced-
CD146 expression in primary tumour compared to control, suggest-
ing less vascularization in treated-primary tumours. We also have
shown that TH1579 decreased the number of Circulating Tumour
Cells (CTC) and Disseminated Tumour Cells (DTC) in lung of treated
mice bearing a non-advanced OS tumour, suggesting that TH1579
might have a direct effect on invasion and migration of tumour cells
[44,45]. We effectively confirmed in vitro that TH1579 reduced inva-
sion and migration of OS cells in line with the literature showing that
MTH1 is required for invasion and migration [24,46]. Indeed, Arczew-
ska et al. demonstrated that MTH1 depletion using siRNA signifi-
cantly reduced invasion and migration of thyroid cancer cell lines by
modulating Matrix Metalloproteinases (MMPs) activity and expres-
sion [46]. MTH1 inhibitor (S)-crizotinib was also described to reduce
migratory ability of OS cells in vitro [24].
Furthermore, associated-bone lesions characterize OS develop-
ment, and no significant change of bone parameters was observed
after TH1579 treatment even if the bone integrity of the tibia is better
than in the control group. These results can be explained by the
smaller tumours in the treated groups compared to the control.
While targeting MTH1 is a contentious question in cancer
research, our study demonstrates an anti-tumour activity of TH1579
both in vitro and in vivo in OS model associated with induction of apo-
ptosis and DNA damage. All these data are the proof of principle that
TH1579 could be considered as alternative therapy in metastatic
osteosarcoma patient.
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